Back

Antisense oligonucleotide to SARS-Cov-2 trs gene: antiviral activity on an in vitro model and possibilities of vital and postmortem diagnosis of COVID-19.

Goryachev, A. N.; Shtro, A. A.; Galochkina, A. V.; Goryacheva, A. S.

2022-08-15 microbiology
10.1101/2022.08.13.503857 bioRxiv
Show abstract

The data on the relevance of the 5 -AGC CGA GTG ACA GCC ACA CAG antisense oligonucleotide for binding to the trs-gene of the SARS-CoV-2 virus, which causes the new coronavirus infection COVID-19, are presented. The high stability and conservatism of this section of the SARS-CoV-2 genome is shown, which allows it to be used as an application point for antisense oligonucleotides. By evaluating plaque inhibition, the ability of this antisense oligonucleotide with phosphorothioate and 2-oxymethyl modification to suppress viral replication was found. The effective dosage reducing the virus titer by 50% is 3.84 mcg/ml. No toxicity was shown up to a dosage of 100 g/mL, which is more than 28.8 chemotherapeutic index. The ability of this oligonucleotide conjugated to the fluorescent dye TAMRA to detect the SARS-CoV-2 virus in the fluorescent hybridization reaction in situ in cytological preparations of nasopharyngeal smears and blood smears, as well as in histological preparations of internal tissues is shown.

Matching journals

The top 8 journals account for 50% of the predicted probability mass.

50% of probability mass above

"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.